Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
8.14
+0.26 (3.37%)
Feb 6, 2026, 11:55 AM EST - Market open
Novavax Revenue
Novavax had revenue of $70.45M in the quarter ending September 30, 2025, a decrease of -16.64%. This brings the company's revenue in the last twelve months to $1.06B, up 20.27% year-over-year. In the year 2024, Novavax had annual revenue of $682.16M, down -30.65%.
Revenue (ttm)
$1.06B
Revenue Growth
+20.27%
P/S Ratio
1.19
Revenue / Employee
$1,118,331
Employees
952
Market Cap
1.32B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 682.16M | -301.54M | -30.65% |
| Dec 31, 2023 | 983.71M | -998.17M | -50.36% |
| Dec 31, 2022 | 1.98B | 835.58M | 72.89% |
| Dec 31, 2021 | 1.15B | 670.69M | 141.02% |
| Dec 31, 2020 | 475.60M | 456.94M | 2,448.48% |
| Dec 31, 2019 | 18.66M | -15.63M | -45.57% |
| Dec 31, 2018 | 34.29M | 3.11M | 9.98% |
| Dec 31, 2017 | 31.18M | 15.82M | 103.06% |
| Dec 31, 2016 | 15.35M | -20.90M | -57.65% |
| Dec 31, 2015 | 36.25M | 5.59M | 18.24% |
| Dec 31, 2014 | 30.66M | 9.74M | 46.59% |
| Dec 31, 2013 | 20.92M | -1.16M | -5.26% |
| Dec 31, 2012 | 22.08M | 7.39M | 50.30% |
| Dec 31, 2011 | 14.69M | 14.35M | 4,182.22% |
| Dec 31, 2010 | 343.00K | 18.00K | 5.54% |
| Dec 31, 2009 | 325.00K | -739.00K | -69.45% |
| Dec 31, 2008 | 1.06M | -449.00K | -29.68% |
| Dec 31, 2007 | 1.51M | -225.00K | -12.95% |
| Dec 31, 2006 | 1.74M | -3.61M | -67.47% |
| Dec 31, 2005 | 5.34M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AnaptysBio | 169.47M |
| Immatics | 99.45M |
| Intellia Therapeutics | 57.53M |
| Capricor Therapeutics | 11.13M |
| Taysha Gene Therapies | 6.31M |
| DBV Technologies | 5.50M |
| AtaiBeckley | 3.02M |
NVAX News
- 7 days ago - Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today? - Seeking Alpha
- 17 days ago - Novavax Announces Entering into a License Agreement with Pfizer - PRNewsWire
- 17 days ago - Novavax enters license agreement with Pfizer for vaccine development - Reuters
- 22 days ago - Novavax, Inc. (NVAX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 2 months ago - FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks - Investopedia
- 2 months ago - Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men - Market Watch
- 2 months ago - Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals - Barrons